Buy Rating Affirmed for Cognition Therapeutics on Promising Alzheimer's Drug Candidate CT1812
Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Cognition Therapeutics Analyst Ratings
Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials
Oppenheimer Sticks to Its Buy Rating for Cognition Therapeutics (CGTX)
Cognition Therapeutics Analyst Ratings
Cognition Therapeutics Analyst Ratings
B.Riley Financial Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Cognition Therapeutics (CGTX)
Cognition Therapeutics (CGTX) Receives a Buy From B.Riley Financial
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Olema Pharmaceuticals (OLMA) and Cognition Therapeutics (CGTX)
Oppenheimer Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)
Oppenheimer Reiterates Outperform on Cognition Therapeutics, Maintains $9 Price Target
Cognition Therapeutics (CGTX) Receives a Buy From B.Riley Financial
B.Riley Financial Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)
Cognition Therapeutics Analyst Ratings
Cantor Fitzgerald Initiates Coverage On Cognition Therapeutics With Overweight Rating, Announces Price Target of $12
Cognition Therapeutics (CGTX) Receives a Buy from B.Riley Financial
No Data